Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

15
290
1
3

Year Published

2015
2015
2024
2024

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 350 publications
(309 citation statements)
references
References 30 publications
15
290
1
3
Order By: Relevance
“…A clinical trial with IL-2 plus rapamycin showed transient worsening in beta cell function [42], likely due to either the relatively higher dose of IL-2 employed and/or the rapamycin, with a dramatic increase in natural killer cells and eosinophils. However, early T1D studies with lower IL-2 doses have shown no acute worsening in b-cell function [66,67], and several studies are underway now to further assess safety and efficacy. In an upcoming phase I trial with autologous ex vivo expanded Tregs followed by low dose IL-2, we will evaluate if low dose IL-2 enhances the survival and function of the infused Tregs in vivo.…”
Section: Combination Therapymentioning
confidence: 99%
“…A clinical trial with IL-2 plus rapamycin showed transient worsening in beta cell function [42], likely due to either the relatively higher dose of IL-2 employed and/or the rapamycin, with a dramatic increase in natural killer cells and eosinophils. However, early T1D studies with lower IL-2 doses have shown no acute worsening in b-cell function [66,67], and several studies are underway now to further assess safety and efficacy. In an upcoming phase I trial with autologous ex vivo expanded Tregs followed by low dose IL-2, we will evaluate if low dose IL-2 enhances the survival and function of the infused Tregs in vivo.…”
Section: Combination Therapymentioning
confidence: 99%
“…Dans le diabète de type 1, des études préliminaires d'efficacité ont permis de déterminer, chez les patients, la dose d'IL-2 induisant une augmentation des lymphocytes Treg sans que ne soient affectées les cellules effectrices T ou NK. Elle a de plus permis de montrer une réduction de la composante T spécifique des cellules β du pancréas [31,32]. L'ensemble de ces premières études indique donc l'intérêt des thérapies fondées sur des faibles doses d'IL-2 pour le traitement des maladies auto-immunes et inflammatoires.…”
Section: (➜)unclassified
“…Less grade II-IV aGVHD (if IL-2 discontinued early) [36] HCV vasculitis 1-3 × 10 6 IU/m 2 /day from days 1 to 5 every 21 days, 4 courses 90% Clinical response [40] Systemic lupus erythematosus 1 × 10 6 IU/m 2 /day every other day for 14 days, 3-6 courses 95% Clinical response [43] Alopecia areata 1-3 × 10 6 IU/m 2 /day from days 1 to 5 every 21 days, 4 courses 80% Clinical response [42] Type1-diabetus 0.3-3 × 10 6 IU/m 2 /day, daily administration for 5 days Selective Treg increase [41] 1 3…”
Section: Resultsmentioning
confidence: 99%
“…Considering the broad clinical relevance of this mechanism, the restoration of normal Treg homeostasis using low-dose IL-2 could be worth considering for the re-induction of tolerance in patients with autoimmunity as well as GVHD. So far, clinical trials for various autoimmune diseases have been performed and promising results were reported in some diseases including systemic lupus erythematosus (SLE) and type-1 diabetes, as shown in Table 1 [40][41][42][43][44]. Ongoing trials are recruiting patients with other autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and so on.…”
Section: Application For Autoimmune Diseasesmentioning
confidence: 99%